Pfizer Global Medical Grants & Partnerships is pleased to announce the latest grant opportunity with colleagues focused on Increasing Awareness & Understanding of Emerging Hemophilia Treatment ...

That’s not just collaboration; that’s commitment, with dollar signs. This strategic partnership exemplifies how global pharma players are bridging borders to tackle complex diseases. By tapping into ...

3SBio, along with its subsidiaries Shenyang Sunshine Pharmaceutical and 3S Guojian Pharmaceutical (Shanghai), will grant Pfizer exclusive global rights to SSGJ-707 outside of China. Pfizer retains ...

3SBio, along with its subsidiaries Shenyang Sunshine Pharmaceutical and 3S Guojian Pharmaceutical (Shanghai), will grant Pfizer exclusive global rights to SSGJ-707 outside of China. Pfizer retains the ...

Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics ... If those results are positive the partners have said they could file for approval in the ...

Pfizer Inc. PFE announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.‘s bispecific antibody SSGJ-707 in a deal potentially worth up to $6 billion. The agreement ...

Pfizer has been granted a global license, excluding China, as well as the option to obtain commercialisation rights in China. 3SBio said separately that the drug has received clearance from the U ...

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China. Pfizer has entered into an exclusive global licensing agreement with 3SBio to ...